BioStem Technologies, Inc. shares are now listed on Nasdaq , expanding access to Capital with a $73 million market cap and 27.3% monthly gain. This uplisting enhances market visibility and Liquidity for shareholders.

Key Highlights

  • The company's shares will continue to trade under the ticker symbol "BSEM" on the Nasdaq Capital Market .
  • BioStem Technologies, Inc.'s market Capitalization stands at approximately $73 million.
  • The company's shares have demonstrated significant growth, with a 52-week range of $3.01 to $10.71.

The company's shares will continue to trade under the ticker symbol "BSEM". This uplisting is expected to enhance market visibility and liquidity for shareholders, with the company's market capitalization standing at approximately $73 million.

Uplisting

to Nasdaq BioStem Technologies, Inc.'s uplisting to the Nasdaq Capital Market reflects the significant progress the company has made in strengthening its foundation, streamlining its operations, and executing on its core Business strategy. The company's common stock is expected to benefit from increased access to capital, improved market visibility, and enhanced liquidity. As a result, shareholders may experience increased trading activity and a more stable stock price.

The uplisting also reinforces the company's ability to attract exceptional talent as it continues to grow.

Market Performance BioStem Technologies, Inc.

shares, up 4.7% year-to-date and 27.3% over the past month, have demonstrated significant growth, with a 52-week range of $3.01 to $10.71. The company's uplisting to the Nasdaq Capital Market is expected to further enhance market visibility and liquidity for shareholders. With a market capitalization of $73 million, the company is well-positioned for continued growth and expansion.

The uplisting may also attract new investors, potentially leading to increased trading activity and a more stable stock price.

Future Growth As BioStem Technologies, Inc.

continues to execute on its core business strategy, the company is poised for future growth and expansion. The uplisting to the Nasdaq Capital Market is expected to provide enhanced access to capital, which may be used to fund Research and Development initiatives, expand the company's product portfolio, and enhance its commercialization efforts. With the company's shares trading on a major exchange, investors will be able to more easily buy and sell the stock, potentially leading to increased liquidity and a more stable stock price.

The company's next Quarterly Report will be closely watched by investors, as it will provide insight into the company's continued growth and expansion.

Peers Moving on This News

  • NeOnc Technologies Holdings Inc (NTHI) up 3.1%
  • Telomir Pharmaceuticals Inc (TELO) down 0.2%

Analysis based on the Form 8-K filed 7 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.